B
REGN icon

Baird’s Regeneron Pharmaceuticals REGN Stock Holding History

Baird’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		$6.23M Sell
13,790
-5,331
-28% -$2.26M 0.06% 297
2014
Q4 		$7.84M Sell
19,121
-143
-0.7% -$56.2K 0.08% 252
2014
Q3 		$6.95M Buy
19,264
+57
+0.3% +$19.1K 0.1% 201
2014
Q2 		$5.42M Buy
19,207
+1,061
+6% +$314K 0.08% 239
2014
Q1 		$5.45M Buy
18,146
+11,255
+163% +$3.47M 0.08% 250
2013
Q4 		$1.9M Buy
6,891
+278
+4% +$80K 0.03% 471
2013
Q3 		$2.07M Buy
6,613
+2,810
+74% +$739K 0.04% 434
2013
Q2 		$855K Buy
+3,803
New +$886K 0.02% 612

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Baird's REGN Position: Q1 2015 in Review

Baird reduced its Regeneron Pharmaceuticals (REGN) stake by 28% in Q1 2015, selling an estimated $2.26M and leaving 13,790 shares worth $6.23M. The position accounts for 0.06% of the portfolio, ranked #297.

Baird first reported a position in REGN in Q2 2013 and has held it in 8 quarters since. The position peaked at $7.84M in Q4 2014. 509 funds tracked by Wall St. Rank hold REGN as of Q1 2015.

  • Baird held 13,790 shares of Regeneron Pharmaceuticals worth $6.23M as of Q1 2015.
  • Baird sold 5,331 Regeneron Pharmaceuticals shares in Q1 2015, an estimated $2.26M.
  • Regeneron Pharmaceuticals made up 0.06% of Baird's portfolio in Q1 2015, its #297 holding.
  • Baird first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 8 quarters since.
  • Baird's Regeneron Pharmaceuticals position peaked at $7.84M in Q4 2014.
  • 509 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2015.

Based on Baird's 13F filing for Q1 2015, filed 13 May 2015.